Intensity Therapeutics regains Nasdaq minimum bid price compliance

INTENSITY THERAPEUTICS, INC.

Nasdaq confirmed compliance with $1.00 minimum bid price after 10 consecutive business days (Feb 19–Mar 4, 2026).
Prior deficiency notice issued June 2025; extension granted until June 1, 2026; matter now closed.
Late-stage clinical biotech focused on intratumoral cancer therapies using proprietary non-covalent conjugation technology.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.